Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

Tommaso De Pas, Filippo De Braud, Mario Mandalà, Giuseppe Curigliano, Chiara Catania, Gianluigi Ferretti, Pietro Sozzi, Piergiorgio Solli, Aron Goldhirsch

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m2 administered on day 1 and VNR 25 mg/m2 administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4-43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.

Original languageEnglish
Pages (from-to)267-270
Number of pages4
JournalLung Cancer
Volume31
Issue number2-3
DOIs
Publication statusPublished - 2001

Keywords

  • Cisplatin
  • Lung cancer
  • Second-line chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine'. Together they form a unique fingerprint.

Cite this